Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells

Kuo, Yung‐Chih; Liang, Cheng-Te

doi:10.1016/j.colsurfb.2011.02.011

Cited by 56 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To achieve this, several strategies have been described, such as linking NPs to glioma CSC relevant antibodies (i.e., CD133, EGFRvIII, EGFR) [95][96][97][98][99][100][101], or binding NPs to specific ligands by exploiting Fig. 2 Summary of the effects elicited by phytocompounds and phytocompound-loaded nanoparticles on glioblastoma CSCs.…”

Section: Discussionmentioning

confidence: 99%

“…Specific targeting of EGFR + U87 cells; inhibition of U87 cell growth; specific targeting of glioma CSCs not reported [100] IONPs conjugated to the EGFR inhibitor cetuximab (Cet-IONPs) Targeting of CD133-independent glioma cells; alteration of EGFR signalling; internalization of EGFR; apoptosis of EGFR + GBM CSCs and neurospheres; increased survival of GBM xenografted rodents upon CEDadministered Cet-IONPs [101] Sendai virus-based liposomes containing Qdots specific to cytosolic EGFR Specific binding of Qdots to intracellular EGFR in GBM and medulloblastoma cell cultures in vitro [102] Polyethylene glycol-poly(lactic-co-glycolic acid) NPs conjugated to Pep-1 (a IL13Rα2 ligand) (Pep-NPs) Efficient targeting of rat C6 glioma cells and penetration into 3D avascular C6 glioma spheroids; this formulation does not allow to selectively target GBM CSCs [103] NPs functionalized with IL-13 and loaded with docetaxel (IL-13-NPs)…”

Section: Np Formulations Effects Referencesmentioning

confidence: 95%

“…EGFR + U87 cells were specifically identified by EGFR-Ab-Dox-CASLNs, which promoted inhibition of cell growth [100]. However, specific targeting of glioma CSC fractions was not assessed in both [99] and [100].…”

Section: Np Formulations Effects Referencesmentioning

confidence: 99%

See 2 more Smart Citations

Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles

et al. 2015

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) are extremely lethal and still poorly treated primary brain tumors, characterized by the presence of highly tumorigenic cancer stem cell (CSC) subpopulations, considered responsible for tumor relapse. In order to successfully eradicate GBM growth and recurrence, new anti-cancer strategies selectively targeting CSCs should be designed. CSCs might be eradicated by targeting some of their cell surface markers and transporters, inducing their differentiation, impacting their hyper-glycolytic metabolism, inhibiting CSC-related signaling pathways and/or by targeting their microenvironmental niche. In this regard, phytocompounds such as curcumin, isothiocyanates, resveratrol and epigallocatechin-3-gallate have been shown to prevent or reverse cancer-related epigenetic dysfunctions, reducing tumorigenesis, preventing metastasis and/or increasing chemotherapy and radiotherapy efficacy. However, the actual bioavailability and metabolic processing of phytocompounds is generally unknown, and the presence of the blood brain barrier often represents a limitation to glioma treatments. Nowadays, nanoparticles (NPs) can be loaded with therapeutic compounds such as phytochemicals, improving their bioavailability and their targeted delivery within the GBM tumor bulk. Moreover, NPs can be designed to increase their tropism and specificity toward CSCs by conjugating their surface with antibodies specific for CSC antigens, with ligands or with glucose analogues. Here we discuss the use of phytochemicals as anti-glioma agents and the applicability of phytochemical-loaded NPs as drug delivery systems to target GBM. Additionally, we provide some examples on how NPs can be specifically formulated to improve CSC targeting.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Np Formulations Effects Referencesmentioning

confidence: 95%

See 1 more Smart Citation

Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In vitro results using human GBM U87MG cells displayed an enhanced drug efficacy compared to the DOX alone as examined by growth inhibition [59]. Drug-loaded liposomes have been made to have long circulating half-lives for slow release kinetics and vasculature normalizing abilities [52].…”

Section: Lipid Nanoparticlesmentioning

confidence: 99%

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Ung

Yang

2015

J Neurooncol

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new treatment strategies are needed to improve overall survival. Immunotherapy has emerged as a potential treatment, but still possesses certain limitations to have a substantial clinical effect. In addition, nanotechnology has emerged as potent treatment effectors that have been shown to augment the effects of therapies including chemotherapy, gene therapy, and more. Nanoparticles possess a novel approach due to the myriad of functional groups that can create targeted treatments, though further optimization is still required. In this review, the authors will present the current uses and abilities of nanotechnology and its implication for use with immunotherapy in the treatment of GBM.

show abstract

“…It breaks the DNA chain of tumor cells by terminating DNA replication [7,8]. Dox is, however, a rather toxic compound with side effects of the gastrointestinal tract and cardiovascular system [9,10]. Sulfonated aluminum phthalocyanine (AlPcS), one of the so-called second-generation photosensitizers, is widely used in PDT because of its good water solubility, intense absorption band in the red light region (where tissue penetration by light is optimal), and high singlet oxygen yield [11,12].…”

Section: Introductionmentioning

confidence: 99%

Conjugation of sulfonated aluminum phthalocyanine to doxorubicin can improve the efficacy of photodynamic cancer therapy

2012

View full text Add to dashboard Cite

Sulfonated aluminum phthalocyanine (AlPcS), a widely used photosensitizer for photodynamic therapy of cancer, was conjugated to doxorubicin (Dox), a chemotherapy drug, through electrostatic binding. The fluorescence resonance energy transfer from Dox to AlPcS showed the formation of AlPcS-Dox conjugates, as the fluorescence intensity of conjugated Dox was decreased and that of the AlPcS moiety was enhanced. This AlPcS-Dox conjugation was further confirmed by electrophoresis. The AlPcS-Dox conjugates enhanced the cellular uptake of AlPcS three times more than unconjugated AlPcS in both human hepatocellular carcinoma cell line 7701 and rat basophilic leukemia cell line. Moreover, the photodynamic killing effect of the conjugates was markedly increased as compared with that of AlPcS alone or the cytotoxicity of Dox alone, showing an enhanced effect of the AlPcS-Dox conjugates. These results indicate that the conjugation of a photosensitizer with a chemotherapy drug may improve photodynamic cancer therapy.

show abstract

Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells

Cited by 56 publications

References 41 publications

Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles

Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Conjugation of sulfonated aluminum phthalocyanine to doxorubicin can improve the efficacy of photodynamic cancer therapy

Contact Info

Product

Resources

About